Hepatitis C: History, Structure, and Treatment Overview
This paper examines the Hepatitis C virus (HCV), the leading cause of chronic liver disease worldwide. Beginning with the virus's discovery around 1989, the paper traces the history of hepatitis strains A through C, then describes HCV's molecular structure and the key enzymes — protease, helicase, and polymerase — that enable its growth. The report explains genome replication, global genotype distribution, and the primary modes of infection, particularly intravenous drug use and blood transfusions. It concludes with an overview of current treatment approaches, including Intron A, ribavirin, and combination therapies, while emphasizing that no vaccine or definitive cure for HCV yet exists.
- Introduction: HCV introduced as leading chronic liver disease cause
- History of Hepatitis Strains: Discovery of HCV and related strains A through C
- Molecular Structure of HCV: Key enzymes identified enabling drug development
- Replication of the Genome: Genotypes, subtypes, and global distribution patterns
- Modes of Infection: Needle sharing, transfusions, and sexual transmission risks
- Current and Potential Treatments: Ribavirin, interferon, and combination therapy options
- Conclusion: Summary of HCV dangers and research findings
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a logical progression from history to biology to clinical treatment, giving the reader a clear narrative arc through a complex medical topic.
- Integrates direct quotations and statistical data from multiple sources (CDC, Columbia Encyclopedia, peer-reviewed journal articles) to support factual claims.
- Contextualizes Hepatitis C by first explaining related strains (A and B), helping a general audience understand the disease's place within a broader viral family.
Key academic technique demonstrated
The paper demonstrates effective use of comparative contextualization — it introduces Hepatitis A and B before Hepatitis C, so readers understand what makes the C strain uniquely dangerous and difficult to treat. This technique grounds new, technical information in familiar reference points and builds reader comprehension incrementally.
Structure breakdown
The paper opens with a hook contrasting alcohol and viral disease as causes of liver failure, then moves through seven clear sections: an introduction to scope, a historical narrative of HCV's discovery and related strains, a molecular structure section, a genome replication section with a detailed characteristics table, a mode-of-infection section, a treatment overview, and a brief conclusion. Each section addresses one defined aspect of the virus, mirroring the structure of a scientific review article.
Introduction
What is the leading cause of liver disease? What could cause so many people to require liver transplants? Most people today would assume the answer is alcoholism. Although alcohol does its fair share of damage to livers around the world, there is a greater source of chronic liver disease at work.
This paper attempts to shed light on the Hepatitis C virus (HCV). There are several strains of the hepatitis virus — some relatively minor and others incurable killers. This report focuses specifically on Hepatitis C, which falls firmly in the latter category and can never be taken lightly.
There are many ways for an individual to contract HCV; however, there is currently no cure once the virus has entered the body. When someone contracts the disease, approximately 75 to 85 percent of those infected will develop chronic liver disease, and of that group, 1 to 5 percent may die from liver-related complications. This report presents the history of the virus, its molecular structure, the replication of its genome, modes of infection, and current treatment methodologies.
History of Hepatitis Strains
Around 1989, after scientists had finally established that the human immunodeficiency virus (HIV) was the primary cause of AIDS, another breakthrough occurred. "A second virus which causes persistent infection — Hepatitis C, or HCV — was identified" (Askari and Cutler). Prior to HCV being identified, the majority of liver failure cases were labeled "cryptogenic" — in plain terms, of unknown cause. In hindsight, scientists now understand what was driving those so-called cryptogenic liver diseases. The virus must have been infecting humans for a very long time. Today, doctors recognize that Hepatitis C was and continues to be the main cause of chronic cirrhosis, liver failure, and liver cancer. Much like HIV infections, Hepatitis C can lie dormant in carriers for many years without producing symptoms. "What is striking about Hepatitis C, in contrast to HIV, is that about 2% of the United States population was already infected with Hepatitis C when the virus was first discovered. HIV is four-fold less common in this country" (Askari and Cutler).
Scientists now know that several viruses can cause acute viral hepatitis in humans. Five strains have been identified to date, classified as Hepatitis A through E. There appear to be additional strains yet to be discovered, with the scientific community tracking at least ten other viruses currently under study. Hepatitis C causes an inflammation of the liver and is currently incurable. An individual can acquire the viral infection from various sources, "including viruses, toxic chemicals, alcohol consumption, parasites and bacteria, and certain drugs. Symptoms of hepatitis are nausea, fever, weakness, loss of appetite, sudden distaste for tobacco smoking, and jaundice" (The Columbia Encyclopedia). To fully understand where we are today with Hepatitis C, it helps to first understand the A and B strains.
Hepatitis A, often called infectious hepatitis, tends to occur in epidemics because the virus is prevalent in human feces. The A strain is easily transmitted through food prepared by someone already infected who has not washed their hands — the very reason health codes require restaurant employees to wash their hands. Active infections are also easily spread through physical contact, but the disease usually resolves on its own. As of 1995, a vaccine using gamma globulin became available, though it is used only in serious cases because it requires a physician-administered injection.
Hepatitis B, often called serum hepatitis, is more difficult to contract than Hepatitis A because it is typically spread through needles. Until the mid-1970s, Hepatitis B was commonly transmitted to patients during blood transfusions. Today, specific blood and plasma screening techniques can identify the strain and largely prevent transfusion-related infections, though these tests cannot eliminate the risk entirely.
Intravenous drug users continue to spread Hepatitis B by sharing contaminated needles. Other transmission routes include sexual contact between partners and transmission from mother to infant during birth. "Some infected individuals, particularly children, become chronic carriers of the virus. Hepatitis B can progress to chronic liver disease and is associated with an increased risk of developing liver cancer" (The Columbia Encyclopedia). A vaccine has been available since 1981 and is recommended for all infants and others at risk. Alpha-interferon was approved as a treatment in 1992.
Hepatitis C was, until it received its current name, simply called non-A or non-B hepatitis. Like the other strains, it can be transmitted through blood transfusions and by sharing contaminated needles. The particular challenge with this strain, however, is that the medical community often cannot identify a specific source of infection. "Many of those infected have no symptoms but become carriers, and the virus may eventually cause liver damage. Blood banks routinely screen for Hepatitis C" (The Columbia Encyclopedia). Hepatitis C has been identified as the primary cause of liver disease and has become the most common form of chronic liver disease. There is no cure, but doctors have begun treating it with Alpha-interferon, as well as a combination approach pairing the drug ribavirin with Alpha-interferon.
Some national statistics illustrate the disease's trajectory: "The number of new infections per year has declined from an average of 240,000 in the 1980s to about 25,000 in 2001. Most infections are due to illegal injection drug use. Transfusion-associated cases occurred prior to blood donor screening; transmission now occurs in fewer than one per million transfused units of blood. An estimated 3.9 million (1.8%) Americans have been infected with HCV, of whom 2.7 million are chronically infected" (Viral Hepatitis C).
Molecular Structure of HCV
When scientists understand the structure of a virus's enzymes, they can design drugs intended to disable those enzymes specifically. Around mid-1991, Schering-Plough made the significant announcement that it had identified the molecular structure of the Hepatitis C virus along with the key enzymes the virus uses to grow and replicate. Those key enzymes are protease, helicase, and polymerase. By the end of 1991, Schering-Plough introduced the new drug Intron A — a relative of interferon, which had already shown effectiveness against multiple sclerosis — that attacked the HCV enzymes identified only months earlier. As predicted, Intron A blocked the virus's ability to grow and replicate. It went on to become the first drug approved by the U.S. Food and Drug Administration specifically for treating Hepatitis C.
Conclusion
This paper attempted to shed light on the Hepatitis C virus. There are several strains of the hepatitis virus — some relatively benign, such as Hepatitis A, and others that are incurable killers. The report focused specifically on Hepatitis C and demonstrated that there are many ways to acquire the virus, and that once it takes hold, liver complications are a common consequence. The paper covered the history of the virus, its molecular structure, the replication of its genome, modes of infection, and current treatment methodologies. Although significant progress has been made in understanding HCV since its identification in 1989, the absence of a vaccine and the limited efficacy of existing drug therapies underscore the continued urgency of research into this pervasive and dangerous virus.
Works Cited
Askari, Fred K., and Daniel S. Cutler. Hepatitis C, the Silent Epidemic: The Authoritative Guide. Cambridge, MA: Perseus Publishing, 1999.
Bacteriology. Ed. IUSM Microbiology Core. IUSM Microbiology Core. 12 Apr. 2004. http://users.ipfw.edu/merkel/MicroCore.html.
Burke, William M., Vasant P. Dhopesh, and Keitha R. Taylor. "Survey of Hepatitis B and C in an Addiction Treatment Unit." American Journal of Drug and Alcohol Abuse 26 (2000).
Hepatitis. Ed. hepatitis-central.com. hepatitis-central.com. 12 Apr. 2004. http://www.hepatitis-central.com/hbv/hepbfaq/other.html.
Horvitz, Leslie Alan. "Hepatitis Afflicts 200 Million; Doctors Help Spread Disease." Insight on the News 11–27 Dec. 1995.
Larson, Ruth. "New Surgeon General Targets Hepatitis C as Deadly Disease." The Washington Times 6 Mar. 1998.
NEA Today. "The ABCs of Hepatitis." NEA Today 13 Apr. 1995.
Price, Joyce Howard. "New Test Screens HIV, Hepatitis C and Other Viruses." The Washington Times 6 Mar. 1999.
The Columbia Encyclopedia. "Hepatitis." The Columbia Encyclopedia. 6th ed. 2000.
Viral Hepatitis C. Ed. CDC. Centers for Disease Control and Prevention. 12 Apr. 2004.
Viral Hepatitis C Fact Sheet. Ed. CDC.Gov. Centers for Disease Control and Prevention. 12 Apr. 2004. http://www.cdc.gov/hepatitis.
Create your account
Always verify citation format against your institution’s current style guide requirements.